Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
48 hedge funds and large institutions have $709M invested in Repare Therapeutics in 2020 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
65.73% more ownership
Funds ownership: 0% → 65.73% (+66%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$110M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$96.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$81.1M |
| 4 |
CA
CHI Advisors
New York
|
+$80.4M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$76.7M |
Top Sellers
RPTX Hedge Fund Activity: Q2 2020 in Review
48 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q2 2020, worth a combined $709M.
Buyers outnumbered sellers: 48 funds opened new RPTX positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $110M.
- 48 institutional investors held Repare Therapeutics (RPTX) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $709M of Repare Therapeutics stock for Q2 2020.
- 48 funds opened new Repare Therapeutics positions in Q2 2020 and 0 closed out, a net change of +48 holders.
- The largest Repare Therapeutics buyer in Q2 2020 was OrbiMed, an estimated $110M added.
Based on aggregated 13F filings for Q2 2020.